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Diabetic retinopathy, a vision-threatening disease, has been regarded as a vascular disorder. However, impaired oscillatory
potentials (OPs) in the electroretinogram (ERG) and visual dysfunction are recorded before severe vascular lesions appear. Here,
we review the molecular mechanisms underlying the retinal neural degeneration observed in the streptozotocin-(STZ-) induced
type 1 diabetes model. The renin-angiotensin system (RAS) and reactive oxygen species (ROS) both cause OP impairment and
reduced levels of synaptophysin, a synaptic vesicle protein for neurotransmitter release, most likely through excessive protein
degradation by the ubiquitin-proteasome system. ROS also decrease brain-derived neurotrophic factor (BDNF) and inner retinal
neuronalcells.TheinﬂuenceofbothRASandROSonsynaptophysinsuggeststhatRAS-ROScrosstalkoccursinthediabeticretina.
Therefore, suppressors of RAS or ROS, such as angiotensin II type 1 receptor blockers or the antioxidant lutein, respectively, are
potential candidates for neuroprotective and preventive therapies to improve the visual prognosis.
1.Introduction
Diabetic retinopathy, a vision-threatening disease, has long
beenregardedasavasculardisorder,whichisstagedclinically
according to the proliferative status of the retinal vasculature
[1]. The disorder involves hemorrhage, vascular obliteration,
and the resulting neovascularization; these events subse-
quently cause ﬁbrovascular proliferation and then retinal
detachment, all of which can secondarily cause retinal neu-
ral degeneration. However, impaired visual function is re-
cordedbeforethemajorvasculardisordersappear[2].More-
over, the atrophic appearance and dysfunction of the neural
retina continue to worsen clinically after the vascular lesions
become quiescent. Therefore, the diabetes-induced retinal
neural degeneration may progress independently of the vas-
cular lesions.
On the other hand, current treatments for diabetic ret-
inopathy are mostly intended to regulate vascular changes
mediated by the action of vascular endothelial growth factor
(VEGF), by laser treatment to attenuate the hypoxic retinal
cells that produce VEGF, and by anti-VEGF drugs, as well
as blood glucose level. The future generation of therapies
is expected to target neural tissue and to elicit a better
visual prognosis. In the retina, a light stimulus activates
the phototransduction pathway in the photoreceptor cells
which span the outer layer of the retina, and is converted
into electric signals which are then processed through the
synaptic network system in the inner layer of the retina
to ﬁnally transmit the signals to the brain to form visual
function. This series of electric reactions in the retina can
be recorded as an electroretinogram (ERG), which is used
to evaluate retinal function objectively, both clinically in
humans and experimentally in animals [2, 3]. Diabetes-
related changes appear in the oscillatory potentials (OPs) in
the ERG of human patients; these changes represent inner
retinaldysfunction.OPchangesindiabeticpatientswereﬁrst
reported in the 1960s [2–4]. However, the molecular mech-
anisms underlying the diabetes-induced neural degeneration
and dysfunction of the retina are still not well understood,
and elucidating them is a current hot topic in the ﬁeld of2 Experimental Diabetes Research
diabetes research. In this paper, we review the molecular
mechanisms of neural degeneration revealed in the retina of
the streptozotocin-(STZ-) induced type 1 diabetes models.
2.STZ-InducedDiabetesModels
Streptozotocin is a glucosamine-nitrosourea compound that
was originally identiﬁed as an antibiotic, but is also known
to have an anticancer eﬀect. It is cytotoxic to pancreatic beta
cells after being transported through glucose transporter 2
(GLUT2)[5]andthereforeisusedtogeneratetype1diabetes
model animals. Experimental diabetes can be induced in
both rats and mice by the intraperitoneal injection of STZ
[6–9]. In the mouse model, the blood glucose level reaches
over 500mg/dL after 1 month of diabetes, compared with
about 100–120mg/dL in control mice [6–9].
Although the above method is often used to make a
diabetes model, there do not appear to be pathological neo-
vascularization caused by vascular obliteration in these an-
imals, which is typical ﬁnding in severe diabetic patients.
However, this model shows apoptosis of the inner retinal
neurons, such as ganglion cells and amacrine cells, and the
activationoftheM¨ ullerglialcellsintheretina[10,11],which
can all contribute to the inner retinal dysfunction detected as
OP changes in the ERG. Interestingly, VEGF, which is found
at a high level in the diabetic retina [7, 12–15], is generally
protective for neurons. Thus, the current treatments, which
target the vascular impairments and VEGF, may not be
eﬀective for the neural pathogenesis. To develop new treat-
ment approaches, it is therefore important to elucidate the
molecular mechanisms underlying the neurodegenerative
changes in diabetic retinopathy. For these studies, the STZ-
induced model is useful, because it mimics the diabetes-
induced OP change in the ERG observed in humans [6, 8,
16, 17].
In the following sections, we describe the molecular
mechanisms of neural degeneration in the retina of the STZ-
induced diabetes model, focusing on the renin-angiotensin
system (RAS) [6, 7, 18, 19] and oxidative stress [8, 20, 21].
3.TheRAS intheNeuralRetinaof Diabetes
The RAS was originally recognized as a regulator of the sys-
temic blood pressure. One of its principal eﬀectors, angi-
otensin II, was originally reported to be converted from a
precursor peptide, angiotensinogen, which is produced in
the liver and then sequentially converted into angiotensin II
by enzymes, renin in the kidney and angiotensin-converting
enzyme (ACE) in the lung, after it enters the circulation.
Angiotensin II promotes vessel contraction to elevate the
blood pressure, and this is known as systemic RAS. On
the other hand, recent studies have revealed that all the
RAS components can be generated within a given tissue
or organ. This is called tissue RAS and is found in the
heart, blood vessels, kidney, adrenal gland, pancreas, central
nervous system, reproductive system, and lymphatic and
adipose tissue [22], as well as the retina [23, 24]. Tissue RAS
can be regulated independently of the systemic RAS [22].
Angiotensin II has long been known to have a role in dia-
betic complications, such as nephropathy and retinopathy,
with evidence indicating that it aﬀects the vascular system
of each organ or tissue [7, 18, 25] via tissue RAS, in a
paracrine fashion [25, 26]. Thus, the common mechanism
of these complications has been believed to be the eﬀects of
angiotensin II on the vascular system [7, 18, 25]. However,
recent studies using the STZ-induced diabetes model have
begun to reveal the inﬂuences of angiotensin II on neural
cells [6, 27].
3.1. Inﬂuence of the RAS on Synapses. In STZ-induced dia-
betes model mice, angiotensin II and its type 1 receptor
(AT1R) are upregulated in the retina [6, 7]. Interestingly,
AT1R is abundantly coexpressed with synaptophysin, a syn-
aptic vesicle protein critical for neurotransmitter release, in
the inner layer of the normal mouse retina (Figure 1)[ 28],
consistent with AT1R signaling role in modulating synaptic
activity in the central nervous system [29].
Kurihara et al. analyzed the role of AT1R in the diabetic
retina by administering the AT1R blockers telmisartan and
valsartan to STZ-induced diabetes model mice [6]. AT1R
blockers suppressed the OP change in this model that
reﬂects impaired inner retinal function. Therefore, the visual
functional impairment in this STZ-induced diabetes model
is,atleastinpart,causedbyAT1Rsignaling.Moreover,AT1R
reduced synaptophysin expression in a posttranscriptional
fashion in the retina of the diabetes model mice. This ob-
servation is consistent with the fact that the visual dysfunc-
tion in this model originates in the inner layer of the retina,
where the synaptic network system is located.
3.2. Direct Inﬂuence of the RAS on Neurons. The molecular
mechanism underlying the decrease in synaptophysin pro-
tein was analyzed using a neuronal cell line originated from a
pheochromocytoma, PC12D. In this cell line, AT1R is coex-
pressed with synaptophysin which is posttranscriptionally
decreased by adding angiotensin II to the culture medium
[6]. This decrease is inhibited by both AT1R blockers and
AT1R knockdown using shRNA. Downstream of AT1R, ERK
is activated, which was also conﬁrmed using inhibitors and
shRNA. This posttranscriptional reduction of synaptophysin
protein results from its excessive degradation through the
ubiquitinproteasomesystem(UPS)[6].Notably,thisinvitro
experiment showed that angiotensin II has a direct eﬀect
on neuronal cells. ERK is activated in the diabetic retina
in vivo, suggesting that the same pathway is involved in
the neuronal pathogenesis in the retina of the STZ-induced
diabetes model. In another report on the eﬀect of an ACE
inhibitor in these model animals, it was concluded that the
drug inhibited retinal degeneration by reducing the blood
pressure and blood glucose level [30]. However, the in vivo
results of Kurihara et al. were obtained under conditions in
which the blood pressure and blood glucose levels did not
change, further supporting the idea that RAS has a direct
eﬀect on neurons in vivo.
The role of angiotensin II in diabetic retinopathy has
beenstudiedclinicallyintheDiabeticRetinopathyCandesar-
tan Trials (DIRECTs) [31, 32], in which the eﬀect of anExperimental Diabetes Research 3
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Figure 1: Expression of angiotensin II type 1 receptor and syn-
aptophysin in the mouse retina. Expression of AT1R (green) in the
normal retina (A–C). The boxed area in A is magniﬁed in B and C
(merged in C), and the boxed areas in C are magniﬁed in the insets
of C. AT1R is coexpressed with synaptophysin (pink), a presynaptic
vesicle protein, in the IPL (arrow in the upper inset of C) and OPL
(arrows in B and the lower inset of C). AT1R, angiotensin II type 1
receptor; GCL, ganglion cell layer; IPL, inner plexiform layer; INL,
inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear
layer [28].
AT1R blocker on the incidence and progression of diabetic
retinopathywasevaluatedusingtheEarlyTreatmentDiabetic
Retinopathy Study (ETDRS) scale. Although this scale has
been established to evaluate vascular lesions of diabetic
retinopathy [33], the eﬀect of the drug may also involve
improving the retinal neural condition taking into account
the data from the animal model [6].
3.3. RAS and UPS. Angiotensin II induces pathological UPS
activity in various tissues, including vascular smooth mus-
cle [34]. Angiotensin II promotes the expression of atrogin-
1, an E3 ubiquitin ligase selective for skeletal muscle wast-
ing [35]. Notably, another animal model of retinal tissue
inﬂammation, endotoxin-induced uveitis and retinitis, in
whichRASisalsoresponsibleforitsneurodegenerativechan-
ges [28], shows the involvement of UPS-mediated exces-
sivedegradation ofrhodopsin, avisualsubstance,intheneu-
ronal dysfunction of the retina [36, 37]. Given that the
RAS contributes to various kinds of diabetic complications,
the UPS may have important roles in the diabetes-induced
pathogenesis, a possibility meriting further study.
4. OxidativeStressin
theNeuralRetinaofDiabetes
Oxidative stress is another key modulator of diabetic com-
plications [8, 20, 38]. Reactive oxygen species (ROS) can be
produced in mitochondria through the electron transport
chain [39, 40]. Keeping the levels of mitochondrial ROS
at normal levels by pharmacological method prevents the
activation of protein kinase C, the formation of advanced
glycation end products, sorbitol accumulation, and NF-κB
activation, all of which are coupled with diabetes-induced
vascular endothelial cell damage [40]. In this section, we in-
troduce the mechanism of oxidative stress-induced neural
degeneration observed in the retina of the STZ-induced dia-
betes model [8].
4.1. Inﬂuence of Oxidative Stress on Synapses. The retinal
neuronal cells are inﬂuenced by ROS: in the STZ-induced
diabetes model mice, both the decrease in synaptophysin
protein and the ERG impairment are suppressed under the
constant administration of an antioxidant, lutein, which
suppresses the local ROS (Figure 2) and ERK activation in
the diabetic retina [8]. This inﬂuence, shown by Sasaki et
al., is observed as early as 1 month from diabetic onset, the
same time as the RAS inﬂuence reported by Kurihara et al.
Since lutein also did not change the blood glucose level in
this analysis, but reduced the ROS level in the retina with
diabetes, the eﬀect of lutein in the retina was, at least in part,
through the reduction of the diabetes-induced local ROS.
Another inﬂuence of ROS related to neuronal activity
is exerted on the expression of brain-derived neurotrophic
factor (BDNF). This factor regulates axonal growth and
synaptic activity as well as neuronal survival [41]. The level
of BDNF in the diabetic retina is decreased [8, 42], but lutein
treatment prevents this reduction [8]. The BDNF level is
regulated by neuronal synaptic activity [43], suggesting that
the mechanism of its preservation in the retina of diabetic
mice by lutein administration may involve the preservation
of synaptophysin protein and the subsequent protection of
neuronal synaptic activity.
In addition to promoting BDNF expression [43], synap-
tic activity promotes neuronal survival through depolar-
ization of the cell membrane and increasing the level of
intracellular calcium in the neuronal cells [44]. Therefore,
the synaptic change observed in the diabetic retina aﬀects,
at least in part, retinal neuronal survival and visual function.
Sasaki et al. showed that the thickness of the inner layer of
the retina, including the retinal ganglion cells and amacrine
cells, in the diabetes model mice is reduced 4 months
after diabetes onset [8], consistent with the previous report
showing similar changes in the model rats 7.5 months after
diabetes onset [10]. However, in lutein-administered mice,
in which the synaptophysin and BDNF levels are preserved
after 1 month of diabetes, the thickness is preserved, and
the neuronal cells survive by constant treatment [8]. Thus,
the antioxidative treatment by lutein appears to protect the
neuronal cells from apoptosis.
The antioxidant, lutein, is presently being studied for
its preventive eﬀects on the progression of age-related
macular degeneration (AMD), a vision-threatening disease,
as a micronutrient supplement. It is a yellow pigment and
can ﬁlter blue light, which has a high energy level that is
toxic to the retina. However, interestingly, the preventive
eﬀect of lutein observed in the retina of the STZ-induced
diabetes model occurs by the ROS reduction rather than
the ﬁltering of light energy. Moreover, the fact that lutein is
physiologically delivered to the retinal neurons [45] suggests
that it might act directly in the retina, and not only as an
antioxidant. Further studies aimed at elucidating whether
lutein’s eﬀects involve pathways other than the antioxidative
pathway should be performed.4 Experimental Diabetes Research
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Figure 2: Oxidative stress in the retina of the STZ-induced diabetes model mouse. Dihydroethidium (DHE) indicates ROS in the retina (a).
The level of diabetes-induced ROS in the retina is decreased by constant lutein treatment. Fluorescence intensity in the INL relative to that
of nondiabetic mice was measured by the Image J program (b). DHE, dihydroethidium; ROS, reactive oxygen species; GCL, ganglion cell
layer; IPL, inner plexiform layer; INL, inner nuclear layer (original copyright; [8], Figure 1, reproduced with the kind permission of Springer
Science + Business Media.)
4.2. Other Inﬂuences of Oxidative Stress in the Retina. The
inﬂuence of diabetes on neural retinal cells has also been
analyzed from other viewpoints. Under diabetic conditions,
the increase in superoxide anions in the neural retina leads to
a decreased bioavailability of nitric oxide which is originally
induced in the retina for tissue protection; the decrease in
nitric oxide action increases the formation of peroxynitrite,
whichinhibitsthedownstreamsignalingofaneuroprotective
factor, nerve growth factor (NGF), and neuronal survival
[46].
M¨ uller glial cells, which contribute to the homeostasis
of the retina, are also damaged by oxidative stress [47, 48].
These cells originate from a common retinal progenitor cell
withneuronalcellsandpopulatetheneuralretina.Therefore,
the damage of these cells can also inﬂuence visual function.
The inﬂuences of oxidative stress on M¨ uller glial cells involve
the downregulation of a potassium channel, Kir4.1, a water
channel, aquaporin 4 [48], and matrix metalloproteinase-7
(MMP-7) which converts a toxic factor for neurons, pro-
nerve growth factor (pro-NGF), to a neuroprotective fac-
tor, NGF [47]. Therefore, there are multiple pathways down-
stream of oxidative stress that can cause retinal neural cell
damage and decrease visual function.
5.CrosstalkbetweenAngiotensinII
andROS Signals
Synaptophysin protein is decreased in the retina of the
STZ-induced diabetes model through both the AT1R-ERK
axis and the ROS-ERK axis, suggesting the involvement
of cross talk between angiotensin II and ROS signals in
the diabetic retina (Figure 3). Angiotensin II can activate
nicotinamide adenine dinucleotide phosphate (NAD(P)H)
oxidase via AT1R stimulation and produces ROS, as shown
in the pathogenesis of atherosclerosis [49–51]. Moreover,
angiotensin 1-7, which are cleaved from angiotensin II and
act as its negative regulators, are reduced in the retina with
diabetes [52], and their overexpression reduces diabetes-
induced oxidative stress in the retina, suggesting that their
reduction might also be related to the cross talk.
Indeed, the eﬀect of angiotensin II on the retinal leu-
kostasis in diabetes occurs at least partly through NAD(P)HExperimental Diabetes Research 5
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Figure 3: Model of retinal neural degeneration and visual im-
pairment in the STZ-induced diabetes model mouse. Cross-talk
between AT1R signaling and ROS is involved in the neural degen-
eration of the diabetic retina. Downstream of both these eﬀectors,
ERK activation reduces synaptophysin, while ROS also decrease
BDNF. These changes impair visual function most probably
through synaptic network abnormalities and neuronal apoptosis.
AT1R, angiotensin II type 1 receptor; ROS, reactive oxygen species;
BDNF, brain-derived neurotrophic factor.
oxidase-related ROS generation, as shown using apocynin,
anNAD(P)Hoxidaseinhibitor,andN-acetylcysteine(NAC),
an antioxidant [53]. The ROS generated downstream of
AT1R further upregulate multiple inﬂammatory cytokines,
such as TNF-α,I L 1 - β,a n dI F N - γ, which further induce ROS
[51]. Collectively, these ﬁndings support the idea that RAS-
ROS cross talk has a large role in the pathogenesis of the
diabetes-induced degeneration of neural tissue.
Another outcome of the cross talk in the diabetic retina
may be the expression of VEGF. M¨ uller glial cells are the
responsible cells for VEGF induction in the diabetic retina,
and this induction is regulated by hypoxia-inducible factor-
1α (HIF-1α)[ 54], which can be activated by oxidative stress
[55]. VEGF induction in the diabetic retina is also regulated
byRAS[7],suggestingthatcrosstalkmayoccurintheM¨ uller
glial cells.
Further studies are required to assess the contribution of
the RAS-ROS interaction in the diabetic retinal degeneration
that leads to impaired visual function and its possibility as a
therapeutic target for this impairment.
6. Summary
Retinal neural cell loss is involved as one of the main causes
for visual deﬁcits in diabetes, and given that the retinal neu-
ral tissue eventually regulates diabetes-induced vascular dis-
orders [54], it is essential to understand the molecular
mechanisms underlying the pathology in the retinal neural
cells to establish the next generation of therapies. To the best
ofourknowledge,atpresenttheangiotensinIImodiﬁersand
antioxidants are the most promising candidates for future
neuroprotectiveandpreventivetherapiesaimedatimproving
neuronal cell survival and normalizing the microenviron-
ment, such as cytokine production in the neural tissue, in
the diabetic retina.
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